

## CLINICAL CANCER RESEARCH

## TABLE OF CONTENTS

## HIGHLIGHTS

3895 Selected Articles from This Issue

## SPECIAL FEATURES

## CCR Translations

3897 **Bridging the Translational Divide in Oncology: *In Vivo* Testing of Chemo-sensitivity**  
Stefan Sleijfer and Martijn Lolkema

See related article, p. 3958

3899 **"All Our Wisdom is Stored in the Trees" - Degrading BCR-ABL with *Berberis Vulgaris***  
Shannon Elisabeth Elf

See related article, p. 4040

## Reviews

3901 **Dendritic Cells, the T-cell-inflamed Tumor Microenvironment, and Immunotherapy Treatment Response**  
Christopher S. Garris and Jason J. Luke3908 **Small-Cell Carcinoma of the Ovary, Hypercalcemic Type-Genetics, New Treatment Targets, and Current Management Guidelines**

**A C** Marc Tischkowitz, Sidong Huang, Susana Banerjee, Jennifer Hague, William P.D. Hendricks, David G. Huntsman, Jessica D. Lang, Krystal A. Orlando, Amit M. Oza, Patricia Pautier, Isabelle Ray-Coquard, Jeffrey M. Trent, Michael Witcher, Leora Witkowski, W. Glenn McCluggage, Douglas A. Levine, William D. Foulkes, and Bernard E. Weissman

## CLINICAL TRIALS: TARGETED THERAPY

3918 **Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study**

**A C** John C. Byrd, Richard R. Furman, Steven E. Coutre, Ian W. Flinn, Jan A. Burger, Kristie Blum, Jeff P. Sharman, William Wierda, Weiqiang Zhao, Nyla A. Heerema, Ying Luan, Emily A. Liu, James P. Dean, and Susan O'Brien

3928 **Randomized Phase II Trial of Carboplatin–Paclitaxel Compared with Carboplatin–Paclitaxel–Trastuzumab in Advanced (Stage III–IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis**

Amanda N. Fader, Dana M. Roque, Eric Siegel, Natalia Buza, Pei Hui, Osama Abdelghany, Setsuko Chambers, Angeles Alvarez Secord, Laura Havrilesky, David M. O'Malley, Floor J. Backes, Nicole Nevadunsky, Babak Edraki, Dirk Pikaart, William Lowery, Karim ElSahwi, Paul Celano, Stefania Bellone, Masoud Azodi, Babak Litkouhi, Elena Ratner, Dan-Arin Silasi, Peter E. Schwartz, and Alessandro D. Santin

3936 **MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP- $\alpha$ , in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial**

**A C** Debashis Sarker, Ruth Plummer, Tim Meyer, Mikael H. Sodergren, Bristi Basu, Cheng Ean Chee, Kai-Wen Huang, Daniel H. Palmer, Yuk Ting Ma, T.R. Jeff Evans, Duncan R.C. Spalding, Madhava Pai, Rohini Sharma, David J. Pinato, James Spicer, Sarah Hunter, Vineet Kwatra, Joanna P. Nicholls, David Collin, Robert Nutbrown, Helen Glenny, Sonia Fairbairn, Vikash Reebye, Jon Voutila, Stephanie Dorman, Pinelopi Andrikakou, Peter Lloyd, Steve Felstead, Jenni Vasara, Robert Habib, Chris Wood, Pal Saetrom, Hans E. Huber, David C. Blakey, John J. Rossi, and Nagy Habib

3947 **Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with *AKT1*<sup>E17K</sup>-Mutant, ER-Positive Metastatic Breast Cancer**

**A C** Lillian M. Smyth, Kenji Tamura, Mafalda Oliveira, Eva M. Ciruelos, Ingrid A. Mayer, Marie-Paule Sablin, Laura Biganzoli, Helen J. Ambrose, Jack Ashton, Alan Barnicle, Des D. Cashell, Claire Corcoran, Elza C. de Bruin, Andrew Foxley, Joana Hauser, Justin P.O. Lindemann, Rhiannon Maudsley, Robert McEwen, Michele Moschetta, Martin Pass, Vicky Rowlands, Gaia Schiavon, Udai Banerji, Maurizio Scaltriti, Barry S. Taylor, Sarat Chandrarapaty, José Baselga, and David M. Hyman

# TABLE OF CONTENTS

**3958**     **Multiplexed Evaluation of Microdosed Antineoplastic Agents *In Situ* in the Tumor Microenvironment of Patients with Soft Tissue Sarcoma**

**A C**     Kenneth R. Gundle, Gary B. Deutsch, Howard J. Goodman, Seth M. Pollack, Matthew J. Thompson, Jessica L. Davis, Mee-Young Lee, Daniel C. Ramirez, William Kerwin, Jessica A. Bertout, Marc O. Grenley, Kimberly H.W. Sottero, Emily Beirne, Jason Frazier, Joyoti Dey, Micah Ellison, Richard A. Klinghoffer, and Robert G. Maki

See related commentary, p. 3897

**3969**     **Low-dose versus High-dose Carfilzomib with Dexamethasone (S1304) in Patients with Relapsed-Refractory Multiple Myeloma**

Sikander Ailawadhi, Rachael Sexton, Suzanne Lentzsch, Muneer H. Abidi, Peter M. Voorhees, Adam D. Cohen, Eric M. Rohren, Stephen Heitner, Kevin Kelly, Niklas J. Mackler, David M. Baer, Antje Hoering, Brian Durie, and Robert Z. Orlowski

## CLINICAL TRIALS: IMMUNOTHERAPY

**3979**     **Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Results of Phase I Trials**

**A C**     Donghua Shi, Yaoping Shi, Ahmed O. Kaseb, Xingxing Qi, Yuan Zhang, Jiachang Chi, Qing Lu, Huiping Gao, Hua Jiang, Huamao Wang, Daijing Yuan, Hong Ma, Hongyang Wang, Zonghai Li, and Bo Zhai

## PRECISION MEDICINE AND IMAGING

**3990**     **First-in-Human Assessment of cRGD-ZW800-1, a Zwitterionic, Integrin-Targeted, Near-Infrared Fluorescent Peptide in Colon Carcinoma**

Kim S. de Valk, Marion M. Deken, Henricus J.M. Handgraaf, Shadhvi S. Bhairosingh, Okker D. Bijlstra, Michiel J. van Esdonk, Anton G.T. Terwisscha van Scheltinga, A. Rob P.M. Valentijn, Taryn L. March, Jaap Vuijk, Koen C.M.J. Peeters, Fabian A. Holman, Denise E. Hilling, J. Sven D. Mieog, John V. Frangioni, Jacobus Burggraaf, and Alexander L. Vahrmeijer

**3999**     **Probody Therapeutic Design of <sup>89</sup>Zr-CX-072 Promotes Accumulation in PD-L1-Expressing Tumors Compared to Normal Murine Lymphoid Tissue**

Danique Giesen, Linda N. Broer, Marjolijn N. Lub-de Hooge, Irina Popova, Bruce Howng, Margaret Nguyen, Olga Vasiljeva, Elisabeth G.E. de Vries, and Martin Pool

**4010**     **Disease Monitoring Using Post-induction Circulating Tumor DNA Analysis Following First-Line Therapy in Patients with Metastatic Colorectal Cancer**

Xiaoju Max Ma, Johanna C. Bendell, Herbert I. Hurwitz, Christine Ju, John J. Lee, Alex Lovejoy, Christoph Mancao, Alan Nicholas, Richard Price, Nicolas Sommer, Nalin Tikoo, Lijing Yao, Stephanie J. Yaung, and John F. Palma

**4018**     **The Immunosuppressive Niche of Soft-Tissue Sarcomas is Sustained by Tumor-Associated Macrophages and Characterized by Intratumoral Tertiary Lymphoid Structures**

**A C**     Lingling Chen, Teniola Oke, Nicholas Siegel, Gady Cojocar, Ada J. Tam, Richard L. Blosser, Jessica Swailes, John A. Ligon, Andriana Lebid, Carol Morris, Adam Levin, Daniel S. Rhee, Fabian M. Johnston, Jonathan B. Greer, Christian F. Meyer, Brian H. Ladle, Elizabeth D. Thompson, Elizabeth A. Montgomery, Woonyoung Choi, David J. McConkey, Robert A. Anders, Drew M. Pardoll, and Nicolas J. Llosa

**4031**     **Valganciclovir as Add-on to Standard Therapy in Glioblastoma Patients**

Giuseppe Stragliotto, Mattia Russel Pantalone, Afsar Rahbar, Jiri Bartek, and Cecilia Söderberg-Naucler

**4040**     **Discovery of Berberine that Targetedly Induces Autophagic Degradation of both BCR-ABL and BCR-ABL T315I through Recruiting LRSAM1 for Overcoming Imatinib Resistance**

Zhao Yin, Guiping Huang, Chunming Gu, Yanjun Liu, Juhua Yang, and Jia Fei

See related commentary, p. 3899

**4054**     **Validation of a Ductal Carcinoma *In Situ* Biomarker Profile for Risk of Recurrence after Breast-Conserving Surgery with and without Radiotherapy**

**A C**     Sheila Weinmann, Michael C. Leo, Melanie Francisco, Charisma L. Jenkins, Todd Barry, Glen Leesman, Steven P. Linke, Pat W. Whitworth, Rakesh Patel, James Pellicane, Fredrik Wärnberg, and Troy Bremer

## TRANSLATIONAL CANCER MECHANISMS AND THERAPY

**4064**     **Longitudinal Monitoring of ctDNA in Patients with Melanoma and Brain Metastases Treated with Immune Checkpoint Inhibitors**

Jenny H. Lee, Alexander M. Menzies, Matteo S. Carlino, Ashleigh C. McEvoy, Shahneen Sandhu, Alison M. Weppeler, Russell J. Diefenbach, Sarah-Jane Dawson, Richard F. Kefford, Michael J. Millward, Zeyad Al-Ogaili, Thien Tra, Elin S. Gray, Stephen Q. Wong, Richard A. Scolyer, Georgina V. Long, and Helen Rizos

# TABLE OF CONTENTS

- 4072 Identification of a RAS-activating *TMEM87A-RASGRF1* Fusion in an Exceptional Responder to Sunitinib with Non-Small Cell Lung Cancer**  
Alissa J. Cooper, Yoshihisa Kobayashi, Dewey Kim, Sarah E. Clifford, Sasha Kravets, Suzanne E. Dahlberg, Emily S. Chambers, Jiaqi Li, Deepa Rangachari, Tom Nguyen, Daniel B. Costa, Michael S. Rabin, Nikhil Wagle, Lynette M. Sholl, Pasi A. Jänne, and Geoffrey R. Oxnard
- 4080 Therapeutic Efficacy of Immune Stimulatory Thymidine Kinase and *fms*-like Tyrosine Kinase 3 Ligand (TK/*Flt3L*) Gene Therapy in a Mouse Model of High-Grade Brainstem Glioma**  
Flor Mendez, Padma Kadiyala, Felipe J. Nunez, Stephen Carney, Fernando M. Nunez, Jessica C. Gauss, Ramya Ravindran, Sheeba Pawar, Marta Edwards, Maria Belen Garcia-Fabiani, Santiago Haase, Pedro R. Lowenstein, and Maria G. Castro
- 4093 A20 and *RBX1* Regulate Brentuximab Vedotin Sensitivity in Hodgkin Lymphoma Models**  
Wei Wei, Yuquan Lin, Zihui Song, Wenming Xiao, Liqi Chen, Jiejing Yin, Yan Zhou, Stefan K. Barta, Michael Petrus, Thomas A. Waldmann, and Yibin Yang
- 4107 Patient-Derived Organoids from Multiple Colorectal Cancer Liver Metastases Reveal Moderate Intra-patient Pharmacotranscriptomic Heterogeneity**  
**AC** Jarle Bruun, Kushtrim Kryeziu, Peter W. Eide, Seyed H. Moosavi, Ina A. Eilertsen, Jonas Langerud, Bård Røsok, Max Z. Totland, Tuva H. Brunzell, Teijo Pellinen, Jani Saarela, Christian H. Bergsland, Hector G. Palmer, Kristoffer W. Brudvik, Tormod Guren, Rodrigo Dienstmann, Marianne G. Guren, Arild Nesbakken, Bjørn Atle Bjørnbeth, Anita Sveen, and Ragnhild A. Lothe
- 4120 Dual Targeting of *CDK4/6* and *BCL2* Pathways Augments Tumor Response in Estrogen Receptor-Positive Breast Cancer**  
James R. Whittle, François Vaillant, Elliot Surgenor, Antonia N. Policheni, Gökür Giner, Bianca D. Capaldo, Huei-Rong Chen, He K. Liu, Johanna F. Dekkers, Norman Sachs, Hans Clevers, Andrew Fellowes, Thomas Green, Huiling Xu, Stephen B. Fox, Marco J. Herold, Gordon K. Smyth, Daniel H.D. Gray, Jane E. Visvader, and Geoffrey J. Lindeman
- 4135 Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer**  
Biagio Ricciuti, Gonzalo Recondo, Liam F. Spurr, Yvonne Y. Li, Giuseppe Lamberti, Deepti Venkatraman, Renato Umeton, Andrew D. Cherniack, Mizuki Nishino, Lynette M. Sholl, Geoffrey I. Shapiro, Mark M. Awad, and Michael L. Cheng
- 4143 Single-Cell Circulating Tumor Cell Analysis Reveals Genomic Instability as a Distinctive Feature of Aggressive Prostate Cancer**  
Paymaneh D. Malihi, Ryon P. Graf, Angel Rodriguez, Naveen Ramesh, Jerry Lee, Ramsay Sutton, Rhett Jiles, Carmen Ruiz Velasco, Emi Sei, Anand Kolatkar, Christopher Logothetis, Nicholas E. Navin, Paul Corn, Ana M. Aparicio, Ryan Dittamore, James Hicks, Peter Kuhn, and Amado J. Zurita
- 4154 FS222, a *CD137/PD-L1* Tetravalent Bispecific Antibody, Exhibits Low Toxicity and Antitumor Activity in Colorectal Cancer Models**  
**AC** Matthew A. Lakins, Alexander Koers, Raffaella Giambalvo, Jose Munoz-Olaya, Robert Hughes, Emma Goodman, Sylwia Marshall, Francisca Wollerton, Sarah Batey, Daniel Gliddon, Mihriban Tuna, and Neil Brewis


**AC** AC icon indicates AuthorChoice

For more information please visit [www.aacrjournals.org](http://www.aacrjournals.org)

# TABLE OF CONTENTS

## ABOUT THE COVER

The cover shows aggregates of immune cells detected in rhabdomyosarcomas, termed tertiary lymphoid structures (TLS). The image depicts fused single chromogenic stains of immune markers clustering in TLS. TIGIT: purple, CD31: red, CD163: white, CSF-1R: yellow, IDO-1: green, CD8: orange, CD4: light blue, CD3: pink. Stem-like T cells reside in these dense antigen-presenting-cell niches within the tumor TLS. TLS are a major player in antitumor immune responses and are organized structures where intratumoral T and B cells are educated to become effector and memory cells capable of recognizing the tumor. For details, see the article by Chen and colleagues on page 4018 of this issue.



# Clinical Cancer Research

**26 (15)**

*Clin Cancer Res* 2020;26:3895-4167.

**Updated version** Access the most recent version of this article at:  
<http://clincancerres.aacrjournals.org/content/26/15>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/26/15>.  
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.